FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2927834900> ?p ?o ?g. }

• W2927834900 endingPage "101" @default.
• W2927834900 startingPage "87" @default.
• W2927834900 abstract "Executive Summary The risk of cervical cancer (CC) among women immunosuppressed for a variety of reasons is well documented in the literature. Although there is improved organ function, quality of life and life expectancy gained through use of immunosuppressant therapy, there may be increased long-term risk of cervical neoplasia and cancer and the need for more intense screening, surveillance, and management. Although guidance for CC screening among HIV-infected women (see Table 1) has been supported by evidence from retrospective and prospective studies, recommendations for CC screening among non-HIV immunosuppressed women remains limited because quality evidence is lacking. Moreover, CC screening guidelines for HIV-infected women have changed because better treatments evolved and resulted in longer life expectancy. The objective of this report was to summarize current knowledge of CC, squamous intraepithelial lesions, and human papillomavirus (HPV) infection in non-HIV immunocompromised women to determine best practices for CC surveillance in this population and provide recommendations for screening. We evaluated those with solid organ transplant, hematopoietic stem cell transplant, and a number of autoimmune diseases. A panel of health care professionals involved in CC research and care was assembled to review and discuss existing literature on the subject and come to conclusions about screening based on available evidence and expert opinion. Literature searches were performed using key words such as CC, cervical dysplasia/squamous intraepithelial lesion, HPV, and type of immunosuppression resulting in an initial group of 346 articles. Additional publications were identified from review of citations in these articles. All generated abstracts were reviewed to identify relevant articles. Articles published within 10 years were considered priority for review. Reviews of the literature were summarized with relevant statistical comparisons. Recommendations for screening generated from each group were largely based on expert opinion. Adherence to screening, health benefits and risks, and available clinical expertise were all considered in formulating the recommendations to the degree that information was available. Results Solid Organ Transplant: Evidence specific for renal, heart/lung, liver, and pancreas transplants show a consistent increase in risk of cervical neoplasia and invasive CC, demonstrating the importance of long-term surveillance and treatment. Reports demonstrate continued risk long after transplantation, emphasizing the need for screening throughout a woman's lifetime. Hematopoietic Stem Cell Transplant: Although there is some evidence for an increase in CC in large cohort studies of these patients, conflicting results may reflect that many patients did not survive long enough to evaluate the incidence of slow-growing or delayed-onset cancers. Furthermore, history of cervical screening or previous hysterectomy was not included in registry study analysis, possibly leading to underestimation of CC incidence rates. Genital or chronic graft versus host disease is associated with an increase in high-grade cervical neoplasia and posttransplant HPV positivity. Inflammatory Bowel Disease: There is no strong evidence to support that inflammatory bowel disease alone increases cervical neoplasia or cancer risk. In contrast, immunosuppressant therapy does seem to increase the risk, although results of observational studies are conflicting regarding which type of immunosuppressant medication increases risk. Moreover, misclassification of cases may underestimate CC risk in this population. Recently published preventive care guidelines for women with inflammatory bowel disease taking immunosuppressive therapy recommend a need for continued long-term CC screening. Systemic Lupus Erythematosus and Rheumatoid Arthritis: The risk of cervical high-grade neoplasia and cancer was higher among women with systemic lupus erythematosus than those with rheumatoid arthritis (RA), although studies were limited by size, inclusion of women with low-grade neoplasia in main outcomes, and variability of disease severity or exposure to immunosuppressants. In studies designed to look specifically at immunosuppressant use, however, there did seem to be an increase in risk, identified mostly in women with RA. Although the strength of the evidence is limited, the increase in risk is consistent across studies. Type 1 DM: There is a paucity of evidence-based reports associating type 1 DM with an increased risk of cervical neoplasia and cancer. Recommendations The panel proposed that CC screening guidelines for non-HIV immunocompromised women follow either the (1) guidelines for the general population or (2) current center for disease control guidelines for HIV-infected women. The following are the summaries for each group reviewed, and more details are noted in accompanying table: Solid Organ Transplant: The transplant population reflects a greater risk of CC than the general population and guidelines for HIV-infected women are a reasonable approach for screening and surveillance. Hematopoietic Stem Cell Transplant: These women have a greater risk of CC than the general population and guidelines for HIV-infected women are a reasonable approach for screening. A new diagnosis of genital or chronic graft versus host disease in a woman post–stem cell transplant results in a greater risk of CC than in the general population and should result in more intensive screening and surveillance. Inflammatory Bowel Disease: Women with inflammatory bowel disease being treated with immunosuppressive drugs are at greater risk of cervical neoplasia and cancer than the general population and guidelines for HIV-infected women are a reasonable approach for screening and surveillance. Those women with inflammatory bowel disease not on immunosuppressive therapy are not at an increased risk and should follow screening guidelines for the general population. Systemic Lupus Erythematosus and Rheumatoid Arthritis: All women with systemic lupus erythematosus, whether on immunosuppressant therapy or not and those women with RA on immunosuppressant therapy have a greater risk of cervical neoplasia and cancer than the general population and should follow CC screening guidelines for HIV-infected women. Women with RA not on immunosuppressant therapy should follow CC screening guidelines for the general population. Type 1 Diabetes Mellitus: Because of a lack of evidence of increased risk of cervical neoplasia and cancer among women with type 1 DM, these women should follow the screening guidelines for the general population." @default.
• W2927834900 created "2019-04-11" @default.
• W2927834900 creator A5010856300 @default.
• W2927834900 creator A5021105630 @default.
• W2927834900 creator A5023657523 @default.
• W2927834900 creator A5040412852 @default.
• W2927834900 creator A5049390876 @default.
• W2927834900 creator A5071007031 @default.
• W2927834900 creator A5078187459 @default.
• W2927834900 creator A5078591313 @default.
• W2927834900 date "2019-04-01" @default.
• W2927834900 modified "2023-10-10" @default.
• W2927834900 title "Guidelines for Cervical Cancer Screening in Immunosuppressed Women Without HIV Infection" @default.
• W2927834900 cites W1506839483 @default.
• W2927834900 cites W1511868785 @default.
• W2927834900 cites W1559690140 @default.
• W2927834900 cites W1609901614 @default.
• W2927834900 cites W1762123818 @default.
• W2927834900 cites W1843374414 @default.
• W2927834900 cites W1894863068 @default.
• W2927834900 cites W1964235542 @default.
• W2927834900 cites W1966548475 @default.
• W2927834900 cites W1969613681 @default.
• W2927834900 cites W1981815093 @default.
• W2927834900 cites W1981989535 @default.
• W2927834900 cites W1983836412 @default.
• W2927834900 cites W1989967236 @default.
• W2927834900 cites W1996287310 @default.
• W2927834900 cites W1998515367 @default.
• W2927834900 cites W2006874095 @default.
• W2927834900 cites W2007938932 @default.
• W2927834900 cites W2012504600 @default.
• W2927834900 cites W2014026543 @default.
• W2927834900 cites W2017398926 @default.
• W2927834900 cites W2020518781 @default.
• W2927834900 cites W2020573981 @default.
• W2927834900 cites W2023993455 @default.
• W2927834900 cites W2024125717 @default.
• W2927834900 cites W2024362830 @default.
• W2927834900 cites W2032364679 @default.
• W2927834900 cites W2039815103 @default.
• W2927834900 cites W2041670738 @default.
• W2927834900 cites W2045123507 @default.
• W2927834900 cites W2049366788 @default.
• W2927834900 cites W2050444138 @default.
• W2927834900 cites W2052176637 @default.
• W2927834900 cites W2052248659 @default.
• W2927834900 cites W2052489835 @default.
• W2927834900 cites W2052723508 @default.
• W2927834900 cites W2057110731 @default.
• W2927834900 cites W2061706070 @default.
• W2927834900 cites W2061782700 @default.
• W2927834900 cites W2064157103 @default.
• W2927834900 cites W2067935750 @default.
• W2927834900 cites W2072075283 @default.
• W2927834900 cites W2072287864 @default.
• W2927834900 cites W2074007950 @default.
• W2927834900 cites W2074347396 @default.
• W2927834900 cites W2077351947 @default.
• W2927834900 cites W2082112921 @default.
• W2927834900 cites W2082941844 @default.
• W2927834900 cites W2086680172 @default.
• W2927834900 cites W2087675279 @default.
• W2927834900 cites W2089548173 @default.
• W2927834900 cites W2091307968 @default.
• W2927834900 cites W2093382617 @default.
• W2927834900 cites W2093630931 @default.
• W2927834900 cites W2095081508 @default.
• W2927834900 cites W2097647692 @default.
• W2927834900 cites W2100151143 @default.
• W2927834900 cites W2100515239 @default.
• W2927834900 cites W2100812202 @default.
• W2927834900 cites W2101196984 @default.
• W2927834900 cites W2104388056 @default.
• W2927834900 cites W2106677962 @default.
• W2927834900 cites W2112734666 @default.
• W2927834900 cites W2117335168 @default.
• W2927834900 cites W2117497925 @default.
• W2927834900 cites W2119563670 @default.
• W2927834900 cites W2125223938 @default.
• W2927834900 cites W2125726664 @default.
• W2927834900 cites W2127705328 @default.
• W2927834900 cites W2128907482 @default.
• W2927834900 cites W2130980347 @default.
• W2927834900 cites W2131550376 @default.
• W2927834900 cites W2132689674 @default.
• W2927834900 cites W2132898959 @default.
• W2927834900 cites W2136111158 @default.
• W2927834900 cites W2141806238 @default.
• W2927834900 cites W2142567358 @default.
• W2927834900 cites W2142996390 @default.
• W2927834900 cites W2144022569 @default.
• W2927834900 cites W2144037573 @default.
• W2927834900 cites W2145150089 @default.
• W2927834900 cites W2146163878 @default.
• W2927834900 cites W2146662658 @default.
• W2927834900 cites W2148422519 @default.
• W2927834900 cites W2150344508 @default.

• next